ARTICLE | Clinical News
Tolenix: Phase II data
January 7, 2013 8:00 AM UTC
Top-line data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix (2 mg tolterodine plus 9 mg pilocarpine) met the co-primary endpoints of redu...